期刊文献+

中国汉族人群CYP2C9常见多态性位点的检测及其与国外其他人群的比较研究 被引量:8

Polymorphism Analysis of CYP2C9 Common Alleles in Han Chinese.
下载PDF
导出
摘要 目的检测中国汉族人群细胞色素P450 2C9(CYP2C9)常见多态性位点的等位基因,为药物基因组学研究提供理论依据。方法用聚合酶链反应产物直接测序和基因克隆测序法对2127例中国汉族人群CYP2C9基因常见多态性位点CYP2C9*1、CYP2C9*2和CYP2C9*3等位基因进行检测,明确其在中国汉族人群中的等位基因及基因型频率分布,并与国外不同人群基因多态性进行比较研究。结果中国汉族人群CYP2C9基因常见等位基因CYP2C9*1、CYP2C9*2和CYP2C9*3的等位基因频率分别为96.94%、0.14%、2.92%,常见基因型CYP2C9*1/*1、CYP2C9*1/*2、CYP2C9*1/*3、CYP2C9*3/*3的基因型频率分别为94.12%、0.28%、5.36%、0.24%。结论中国汉族人群CYP2C9基因中以CYP2C9*1等位基因为最常见,CYP2C9*2和CYP2C9*3是中国汉族人群罕见等位基因;中国人群CYP2C9基因的等位基因频率与日本人群相近,与法国、西班牙和意大利等欧洲人群差异有统计学意义,该研究结果将为我国的临床药物基因组学研究提供有价值的理论依据。 Objective To investigate the genetic polymorphism of CYP2C9 in Han Chinese population and compare the distribution profile of CYP2C9 polymorphism with that of other races. Methods PCR combined with DNA sequencing method was used to analyze the sequences of CYP2C9 in 2127 healthy people from Han population in China. Results The allele frequencies of CYP2C9 * 1, CYP2C9 * 2and CYP2C9 * 3 were 96.94% , 0. 14% , 2.92% respectively. The genotype frequencies of CYP2C9 * 1/* 1, CYP2C9 * 1/* 2, CYP2C9 * 1/* 3 and CYP2C9 * 3/* 3 were 94.12% , 0.28% , 5.36% , and 0.24% respectively. Conclusion Our results showed that the distribution profile of CYP2C9 common alleles in Han population is similar to that of population in Japanese, whereas it is significantly different from that of French, Spain and Italian populations. The present data resulted from our study will be useful for the clinical drug therapy, especially for individual medicine of Han Chinese population.
出处 《医学研究杂志》 2011年第6期27-30,共4页 Journal of Medical Research
基金 科技部重大新药创制心脑血管疾病新药临床评价技术平台研究(2008ZX09312-005)
关键词 CYP2C9 基因多态性 基因分型 CYP2C9 Genetic polymorphism Genotyping
  • 相关文献

参考文献13

  • 1Van Booven D, Marsh S, McLeod H, et al. Cytochrome P450 2C9 - CYP2C9[J]. Pharmacogenet Genomics, 2010,20(4) :277 -281 http://www, cypalleles, ki. se/CYP2C9, htm.
  • 2http://www, cypalleles, ki. se/CYP2C9, htm.
  • 3Blaisdell J, Jorge - Nebert LF, Coulter S, et al. Discovery of new po- tentially defective alleles of human CYP2C9[J]. Pharmacogenetics, 2004, 14(8) :527 -537.
  • 4Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients:genetic analysis of the CYP2C9 locus[ J]. Pharmacogenetics,2000,10( 1 ) :85 - 89.
  • 5Sullivan - Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9 - Leu359 allelic variant in the tolbutamide polymorphism [ J ]. Pharmacogenetics, 1996,6 ( 4 ) :341 - 349.
  • 6Yang JQ, Morin S, Verstuyft C, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations[J]. Fun- dam Clin Pharmacol, 2003,17 (3) :373 - 376.
  • 7Garcia - Martin E, Martinez C, Ladero JM, et al. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian pop- ulation[ J]. Eur J Clin Pharmacol, 2001, 57( 1 ) :47 -49.
  • 8Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymor- phism in a Japanese population [ J ]. Pharmacogenetics, 1997,7 ( 5 ) : 405 - 409.
  • 9Scordo MG, Caputi AP, D'Arrigo C, et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population [ J ]. Pharmacol Res. ,2004,50 (2) : 195 - 200.
  • 10Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping:frequencies of mutant alleles in a Swedish popu- lation [ J ]. Biochem Biophys Res Commun, 1999,254 ( 3 ) : 628 - 631.

同被引文献107

  • 1中国心血管健康与疾病报告编写组,王增武,胡盛寿.中国心血管健康与疾病报告2019概要[J].中华老年病研究电子杂志,2020(4):4-15. 被引量:943
  • 2陈騉,王睿.药物代谢酶细胞色素P4502C9研究进展[J].中国临床药理学与治疗学,2004,9(6):601-606. 被引量:15
  • 3MCDONALD M G, RIEDER M J, NAKANO M, et al. CYP4F2 is a vitamin K1 oxidase:an explanation for ahered warfarin dose in carriers of the V433M variant [J]. Mol Pharmaco1,2009,75 ( 6 ) : 1337-1346.
  • 4D' ANDREA G, D'AMBROSIO R L, PEMA P D, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-antociagulant effect of warfarin [ J ]. Blood, 2005,105 ( 2 ): 645-649.
  • 5STUBBINS M J, HARRIES L W, SMITH G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus [ J ]. Pharm acogenetics, 1996,6 ( 5 ) : 429-439.
  • 6TAUBE J, HALSALL D, BAQLIN T. Influence of cytoc- hrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over anticoagulation in patients on long-term treatment [ J]. Blood ,2000,96( 5 ) : 1816-1819.
  • 7HIGASHI M K, VEENSTRA D L, KONDO L M, et al. Association between CYP2C9 genetic variants and an ticoagulation-related outcomes during warfarin therapy [ J ]. JAMA,2002,287 ( 13 ): 1690-1698.
  • 8TOPIC E, STEFANOVIC M, SAMARDZIJA M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype [ J ]. Clin Chem Lab Med,2004,42 ( 1 ) :72-78.
  • 9BOTTON M R, BANDINELLI E, ROHDE L E, et al. Influ- ence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry [ J ]. Br J Clin Pharmaeo1,2011,72 ( 3 ) : 442 -450.
  • 10MONTES R, GAONA E R, MARTINEZ-GONZALEZ M A, et al. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acemocoumarol in anticoagulated patients [ J ]. Br J Haematol, 2006,133 ( 2 ) : 183-187.

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部